Earnings
Home›Earnings›Previews›Boston Scientific shares slip after weaker U.S. Electr…
Boston Scientific shares slip after weaker U.S. Electrophysiology and Watchman
The fund letter cited lowered 2026 organic sales growth guidance to 10% to 11% after CHAMPION AF data did not provide a positive catalyst.
TCW Funds highlighted Boston Scientific Corporation as one of the names featured in its second-quarter 2026 investor letter for the TCW Concentrated Large Cap Growth Fund, pointing to company-specific drivers behind relative performance. In the letter, the firm said overall market gains during the quarter were supported by resilient economic growth and strong corporate earnings, but Boston Scientific was a notable drag within the fund's healthcare exposure.
According to the letter, Boston Scientific shares moved lower after the company’s quarterly results and its CHAMPION AF data results. While the results modestly beat expectations, two franchises, U.S. Electrophysiology and Watchman, missed consensus, which weakened investor sentiment.
TCW also said management lowered 2026 organic sales growth guidance to a range of 10% to 11%. The letter described WATCHMAN’s durability and growth trajectory as a key focus for investors, and it noted that although the CHAMPION-AF data released at the end of March hit all endpoints, it failed to act as a positive catalyst for the shares.
Separately, Boston Scientific closed at $51.42 per share on August 12, 2026, the letter said, while adding that the stock had a one-month return of 15.24% and had fallen 50.63% over the past 52 weeks. The company’s market capitalization was cited at $74.52 billion.